BACKGROUND JAKi represent a new important class in Rheumatoid Arthritis (RA) treatment options. It is unknown which specific bDMARD or mode of action should be selected after stopping a JAKi. OBJECTIVES To study if clinical response differs between advanced therapies that are initiated after stopping a JAKi. METHODS Patients were included from the electronic platform “Tool for Administrative Reimbursement Drug Information Sharing†(TARDIS). Data from all Belgian RA patients on biologic and targeted therapy are collected here for drug reimbursement. Patients were selected for this analysis if they had stopped JAKi therapy and initiated a subsequent therapy. Patients were grouped by TNFi, T/B cell therapy, IL6i or JAKi therapy. The DAS28 response and proportion of patients in remission at the first follow-up (between 3 and 6 months) were compared between groups. Remission was defined as DAS28<2.6. Analyses were repeated in patients who were prescribed the stopped JAKi as first-line or as subsequent line therapy. Data were compared via χ2, Anova and t-tests. RESULTS In total, 1238 patients who had stopped JAKi therapy were included. TNFi, T/B cell therapy, IL6i or JAKi therapy was initiated in 36% (441/1238), 19% (233/1238), 18% (227/1238) and 27% (337/1238) respectively. Most baseline demographic and clinical characteristics differed between groups (Table 1).[…]